Molecular mechanisms involved in the effects of morin in experimental hepatic encephalopathy
- PMID: 35332953
- DOI: 10.1002/biof.1838
Molecular mechanisms involved in the effects of morin in experimental hepatic encephalopathy
Abstract
This study aimed to investigate the possible usefulness of morin flavonoid in comparison to silymarin as a hepatic/neuronal-supportive agent with similar effects and higher bioavailability in a rat model of hepatic encephalopathy (HE). Morin effects on rat liver and brain were evaluated post-induction of HE by thioacetamide (TAA; 200 mg/kg/day for 3 successive days). Then, the serum activities of aspartate transaminase (AST) and alanine transaminase (ALT) together with ammonia concentration were estimated to assess the liver function. Also, the degree of brain effects was evaluated via the assessment of brain contents of reduced glutathione (GSH), malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-α), and interleukin (IL-1β) together with glutathione peroxidase (GPx) activity. In addition, the apoptotic and inflammatory changes in brain and liver tissues were also assessed via immunohistochemical examination. Our findings revealed a promising effect of morin against HE complications; as it corrected the liver functions, attenuated the brain/liver tissue injuries, and reduced the apoptotic and inflammatory insults of HE on both organs. These effects are comparable to those of silymarin. Morin could be introduced as a promising hepato- and neuro-therapeutic adjuvant in HE-associated neuronal complications especially in cases like silymarin intolerance.
Keywords: Morin; apoptosis; hepatic encephalopathy; inflammation oxidative stress.
© 2022 International Union of Biochemistry and Molecular Biology.
References
REFERENCES
-
- Saucedo. Harmful use of alcohol: alcohol use disorders and alcoholic liver diseases. Priority medicines for Europe and the world: A Public Health Approach to Innovation “Update on 2004.” Background Paper, BP 614 Alcohol Use Disorders.
-
- Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145. https://doi.org/10.1186/s12916-0140145-y
-
- Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473-9. https://doi.org/10.1056/NEJM199708143370707
-
- Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83-100. https://doi.org/10.1586/17474124.2014.858598
-
- Amodio P. Current diagnosis and classification of hepatic encephalopathy. J Clin Exp Hepatol. 2018;8:432-7. https://doi.org/10.1016/j.jceh.2018.07.001
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
